Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEL-212 in refractory chronic gout
NCT04596540Phase 3Completed
- Sponsor
- Sobi
- Start
- Nov 2020
- Primary completion
- Jan 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of SEL-212 in gout, sponsored by Sobi. Started Nov 2020; status: completed.
02
Drugs
SEL-212
03
Conditions
gout
Beyond the preview
Go deeper on NCT04596540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04596540.